FDA moves to fast-track review of 3 psychedelic drug studies

The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies ...

FDA moves to fast-track review of psilocybin and methylone for mental health

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...
Hosted on MSN

FDA fast-tracks psychedelic therapies under new review vouchers

The FDA has introduced a new class of accelerated review vouchers for three psychedelic therapy programs targeting depression and PTSD, potentially reducing review times from up to a year to as little ...

Highlights of the Supreme Court Argument on Temporary Protected Status

The arguments suggested that the decision may come down to the votes of two justices, and that any victory for some 356,000 ...
Science Daily

Breakthrough compounds may reverse nerve damage caused by multiple sclerosis

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

The FDA Is Fast-Tracking Review Of Psychedelics—What It Means For Mental Health Treatment

The FDA’s move follows an executive order from President Donald Trump earlier this month that paved the way for more ...

FDA moves to fast-track review of three psychedelic drugs for mental health

The FDA said it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, ...